EP0549723A1 - Cellules d'encapsidation - Google Patents
Cellules d'encapsidationInfo
- Publication number
- EP0549723A1 EP0549723A1 EP91919095A EP91919095A EP0549723A1 EP 0549723 A1 EP0549723 A1 EP 0549723A1 EP 91919095 A EP91919095 A EP 91919095A EP 91919095 A EP91919095 A EP 91919095A EP 0549723 A1 EP0549723 A1 EP 0549723A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- vector
- packaging
- cell line
- retroviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02019446A EP1285967A3 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des rétrovirus |
EP97121096A EP0854193A1 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des Rétrovirus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58660390A | 1990-09-21 | 1990-09-21 | |
US586603 | 1990-09-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97121096A Division EP0854193A1 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des Rétrovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0549723A1 true EP0549723A1 (fr) | 1993-07-07 |
Family
ID=24346413
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97121096A Ceased EP0854193A1 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des Rétrovirus |
EP02019446A Withdrawn EP1285967A3 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des rétrovirus |
EP91919095A Withdrawn EP0549723A1 (fr) | 1990-09-21 | 1991-09-20 | Cellules d'encapsidation |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97121096A Ceased EP0854193A1 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des Rétrovirus |
EP02019446A Withdrawn EP1285967A3 (fr) | 1990-09-21 | 1991-09-20 | Lignée cellulaire humaine pour l'empaquetage des rétrovirus |
Country Status (5)
Country | Link |
---|---|
EP (3) | EP0854193A1 (fr) |
JP (3) | JPH06500923A (fr) |
AU (2) | AU665176B2 (fr) |
CA (1) | CA2092195C (fr) |
WO (1) | WO1992005266A2 (fr) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US6027722A (en) * | 1990-10-25 | 2000-02-22 | Nature Technology Corporation | Vectors for gene transfer |
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
WO1993020221A1 (fr) * | 1992-04-03 | 1993-10-14 | Young Alexander T | Therapie genique utilisant des vecteurs viraux cibles |
AU4259193A (en) * | 1992-04-28 | 1993-11-29 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
DE69333115D1 (de) * | 1992-09-22 | 2003-08-28 | Biofocus Discovery Ltd | Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren |
EP0746625B1 (fr) * | 1992-11-09 | 2004-03-31 | THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Particules vectorielles pouvant etre ciblees |
US6534051B1 (en) | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
CA2156725A1 (fr) * | 1993-02-22 | 1994-09-01 | Warren S. Pear | Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire |
EP0688358A4 (fr) | 1993-03-12 | 1997-10-01 | Univ Creighton | Vecteurs ameliores en therapie genique |
FR2707091B1 (fr) | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
FR2716461A1 (fr) * | 1994-02-22 | 1995-08-25 | Univ Paris Curie | Système hôte-vecteur utilisable en thérapie génique. |
FR2716459B1 (fr) * | 1994-02-22 | 1996-05-10 | Univ Paris Curie | Système hôte-vecteur utilisable en thérapie génique. |
DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
WO1995033842A1 (fr) * | 1994-06-07 | 1995-12-14 | Immunomedics, Inc. | Vecteurs retroviraux sans danger, leur production et utilisation |
CA2196208A1 (fr) * | 1994-08-17 | 1996-02-22 | Michael Pensiero | Vecteurs retroviraux produits par des lignees de cellules productrices resistantes a la lyse par le serum humain |
US5698446A (en) * | 1994-09-07 | 1997-12-16 | Chiron Corporation | Methods and compositions for inhibiting production of replication competent virus |
DK0787191T4 (da) | 1994-10-20 | 2012-01-30 | Pasteur Institut | Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener |
FR2727429B1 (fr) | 1994-11-30 | 1997-11-28 | Haguenauer Odile Cohen | Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs |
US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
US6365344B1 (en) | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
DK0877752T3 (da) | 1996-01-23 | 2003-09-15 | Univ Leland Stanford Junior | Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler |
US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
ATE424463T1 (de) * | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
US5739018A (en) * | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
JP2001500738A (ja) | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | 細胞内疾患を処置するための組成物および方法 |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US6300488B1 (en) | 1997-07-10 | 2001-10-09 | The Salk Institute For Biological Studies | Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression |
WO1999006576A1 (fr) | 1997-08-04 | 1999-02-11 | Calydon, Inc. | Sequence stimulatrice de la kallicreine glandulaire chez l'homme, vecteurs comprenant cette sequence et procedes d'utilisation de ces derniers |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
BR9813930A (pt) | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
EP1047784B2 (fr) | 1998-01-14 | 2015-03-18 | Novartis Vaccines and Diagnostics S.r.l. | Antigenes du neisseria meningitidis |
NZ532665A (en) | 1998-05-01 | 2005-11-25 | Inst Genomic Research | Neisseria meningitidis antigens and compositions |
US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
WO2000022130A2 (fr) | 1998-10-15 | 2000-04-20 | Chiron Corporation | Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
DE69939599D1 (de) | 1998-12-16 | 2008-10-30 | Novartis Vaccines & Diagnostic | MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE) |
CA2365655A1 (fr) * | 1999-03-15 | 2000-09-21 | Chiron Corporation | Procedes de production d'une lignee cellulaire produisant un vecteur utilisant une pluralite de transductions |
NZ571167A (en) | 1999-04-30 | 2010-05-28 | Novartis Vaccines & Diagnostic | Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
US7504253B2 (en) | 1999-06-11 | 2009-03-17 | The Burnham Institute For Medical Research | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
US7057015B1 (en) | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
EP2975127A1 (fr) | 1999-10-29 | 2016-01-20 | GlaxoSmithKline Biologicals SA | Peptites antigènes de neisseria |
JP2003516731A (ja) | 1999-11-18 | 2003-05-20 | カイロン コーポレイション | ヒトfgf−21遺伝子および遺伝子発現産物 |
EP2275129A3 (fr) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Vaccin omv complèté contre la méningocoque |
WO2001064920A2 (fr) | 2000-02-28 | 2001-09-07 | Chiron Spa | Expressions hybrides de proteines de neisseria |
WO2001066595A2 (fr) | 2000-03-08 | 2001-09-13 | Chiron Corporation | Gene humain fgf-23 et produits d'expression associes |
CA2403205A1 (fr) | 2000-03-13 | 2001-09-20 | Engene, Inc. | Compositions et methodes destinees a l'expression regulee d'une proteine dans l'intestin |
GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
GB0024550D0 (fr) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
SG165981A1 (en) | 2000-10-27 | 2010-11-29 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
WO2002081639A2 (fr) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 et ses utilisations diagnostiques et therapeutiques |
WO2002081641A2 (fr) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 et utilisations diagnostique et therapeutique de ce gene |
AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
CA2344208A1 (fr) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Methode |
EP2335723A1 (fr) | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation contre la Chlamydia trachomatis |
ES2411981T3 (es) | 2002-02-01 | 2013-07-09 | Oxford Biomedica (Uk) Limited | Vector lentivírico |
US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
PT2279746E (pt) | 2002-11-15 | 2013-12-09 | Novartis Vaccines & Diagnostic | Proteínas de superfície de neisseria meningitidis |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
CN104292321A (zh) | 2004-03-29 | 2015-01-21 | 株式会社嘉尔药物 | 新的半乳凝素9 突变体蛋白质及其用途 |
WO2006007539A1 (fr) * | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Lignee cellulaire d'encapsidation de vecteurs |
CA2524619A1 (fr) | 2005-11-22 | 2007-05-22 | Ottawa Health Research Institute | Nouvelles cellules souches, sequences nucleotides et proteines provenant de celles-ci |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
EP2431053A1 (fr) | 2006-11-27 | 2012-03-21 | Patrys Limited | Nouvelle cible de peptide glycosylé dans des cellules néoplastiques |
MX2009008413A (es) | 2007-02-06 | 2009-11-02 | Tai June Yoo | Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. |
WO2008116116A2 (fr) | 2007-03-20 | 2008-09-25 | Harold Brem | Compositions gm-csf cosméceuticales et leurs procédés d'utilisation |
WO2009058451A2 (fr) | 2007-08-02 | 2009-05-07 | California Stem Cell, Inc. | Cellules progénitrices neuronales et procédés de dérivation et de purification de cellules progénitrices neuronales de cellules souches embryonnaires |
EP2215269B1 (fr) | 2007-10-15 | 2017-12-13 | Admedus Vaccines Pty Limited | Système de construction et utilisations pour celui-ci |
US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
CA2715373C (fr) | 2008-02-15 | 2019-11-05 | Tufts University | Modele humanise de la formation du complexe d'attaque membranaire (mac) sur la retine murine et compositions, trousses et procedes de traitement de la degenerescence maculaire |
US8999919B2 (en) | 2008-10-22 | 2015-04-07 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between CFTR and CAL |
US8211487B2 (en) | 2008-11-26 | 2012-07-03 | Srinivasan Damodaran | Inhibition of ice crystal growth |
EP2417984B1 (fr) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Procédé pour le traitement d'une tumeur sanguine utilisant un anticorps anti-tim-3 |
WO2010126066A1 (fr) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | Anticorps anti-il-3rα destiné à être utilisé dans le traitement d'hématomes |
SG10201701942VA (en) | 2009-06-17 | 2017-05-30 | Tocagen Inc | Producer cells for replication competent retroviral vectors |
WO2011060233A1 (fr) | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anticorps anti-tem1 et leurs utilisations |
GB0920775D0 (en) | 2009-11-26 | 2010-01-13 | King S College | Cells |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
WO2012021891A2 (fr) | 2010-08-13 | 2012-02-16 | Tufts University | Compositions, kits et méthodes de traitement de pathologies associées au complément |
US9198975B2 (en) | 2010-12-01 | 2015-12-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeting sites of neovascular growth |
AU2012308240A1 (en) | 2011-09-15 | 2013-05-02 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Immunotherapy and diagnosis of mucormycosis using CotH |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
WO2014124334A2 (fr) | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Anticorps anti-transthyrétine et leurs utilisations |
US10166300B2 (en) | 2013-06-04 | 2019-01-01 | Virginia Commonwealth University | Tripartite cancer theranostic nucleic acid constructs |
WO2014197599A1 (fr) | 2013-06-04 | 2014-12-11 | The Johns Hopkins University | Expression en surface de l'avidine/streptavidine, médiée par peg-prom |
US9701985B2 (en) | 2013-06-04 | 2017-07-11 | Virginia Commonwealth University | mda-9/syntenin promoter to image and treat metastatic cancer cells |
EP3003022B1 (fr) | 2013-06-04 | 2017-11-22 | Virginia Commonwealth University | Utilisation d'un promoteur de ccn1 tronqué pour le diagnostic, la thérapeutique et la théragnostique de cancer |
EP3004153B1 (fr) | 2013-06-04 | 2019-10-30 | Virginia Commonwealth University | Cytokines thérapeutiques recombinantes contre le cancer |
US20160152952A1 (en) | 2013-06-25 | 2016-06-02 | Temple University-Of The Commonwealth System Of Higher Education | Cortical Bone-Derived Stem Cells |
GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
WO2015148683A1 (fr) | 2014-03-26 | 2015-10-01 | Tocagen Inc. | Vecteur rétroviral à activité de stimulation immunitaire |
JP6651506B2 (ja) | 2014-08-28 | 2020-02-19 | タフツ・ユニバーシティ | 補体関連障害を処置するための組成物、方法およびキット |
GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
US9901639B2 (en) | 2015-02-13 | 2018-02-27 | Temple University—Of the Commonwealth System of Higher Education | Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
US10596248B2 (en) | 2015-12-09 | 2020-03-24 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
GB201603372D0 (en) * | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Cell |
EP3299460A1 (fr) | 2016-09-26 | 2018-03-28 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Nouveaux composes et procedes destines a moduler l'expression de l'ubiquitination |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
AU2019216975A1 (en) | 2018-02-12 | 2020-09-03 | Trustees Of Tufts College | CD59 for inhibiting inflammasome activation |
EP4013788A1 (fr) | 2019-08-12 | 2022-06-22 | Purinomia Biotech, Inc. | Méthodes et compositions pour favoriser et potentialiser des réponses immunitaires à médiation par des lymphocytes t par ciblage adcc de cellules exprimant cd39 |
WO2021074695A1 (fr) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | FRACTIONS DE MÉDICAMENTS BISPÉCIFIQUES DE L'INHIBITEUR DE PD-L1 ET DE L'INHIBITEUR DE TGFβ |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022234003A1 (fr) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Polypeptides se liant à cd33 avec protéine stefin a |
WO2023057946A1 (fr) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Polypeptides sériques de liaison pd-l1 prolongés à demi-vie |
WO2023057567A1 (fr) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Affimers de liaison à pd-l1 |
WO2023089564A1 (fr) | 2021-11-19 | 2023-05-25 | Janssen Biotech, Inc. | Méthode de traitement d'une atrophie géographique avec un vecteur de thérapie génique exprimant cd59 soluble |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1782288A (en) * | 1987-04-23 | 1988-12-02 | State of Oregon Acting by and through the State Board of Higher Education on behalf ofOregon Health Sciences University | Process for the amplifying expression and transmission of cloned genes in eukaryotic cells |
WO1989009271A1 (fr) * | 1988-03-21 | 1989-10-05 | Viagene, Inc. | Retrovirus recombinants |
JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
EP1001032A3 (fr) * | 1989-08-18 | 2005-02-23 | Chiron Corporation | Rétrovirus de recombinaison apportant des constructions de vecteur à des cellules cibles |
WO1991019803A1 (fr) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes |
-
1991
- 1991-09-20 CA CA002092195A patent/CA2092195C/fr not_active Expired - Fee Related
- 1991-09-20 JP JP3517555A patent/JPH06500923A/ja not_active Withdrawn
- 1991-09-20 EP EP97121096A patent/EP0854193A1/fr not_active Ceased
- 1991-09-20 WO PCT/US1991/006852 patent/WO1992005266A2/fr not_active Application Discontinuation
- 1991-09-20 EP EP02019446A patent/EP1285967A3/fr not_active Withdrawn
- 1991-09-20 EP EP91919095A patent/EP0549723A1/fr not_active Withdrawn
- 1991-09-20 AU AU88424/91A patent/AU665176B2/en not_active Expired
-
1996
- 1996-03-07 AU AU47984/96A patent/AU690427B2/en not_active Expired
-
2002
- 2002-11-21 JP JP2002338657A patent/JP2003159062A/ja active Pending
-
2003
- 2003-10-01 JP JP2003343855A patent/JP4092278B2/ja not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
See references of WO9205266A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP4092278B2 (ja) | 2008-05-28 |
JP2004041234A (ja) | 2004-02-12 |
JP2003159062A (ja) | 2003-06-03 |
EP0854193A1 (fr) | 1998-07-22 |
CA2092195C (fr) | 2000-04-18 |
WO1992005266A3 (fr) | 1992-07-23 |
AU665176B2 (en) | 1995-12-21 |
CA2092195A1 (fr) | 1992-03-22 |
JPH06500923A (ja) | 1994-01-27 |
AU690427B2 (en) | 1998-04-23 |
AU8842491A (en) | 1992-04-15 |
AU4798496A (en) | 1996-06-20 |
EP1285967A2 (fr) | 2003-02-26 |
EP1285967A3 (fr) | 2005-03-02 |
WO1992005266A2 (fr) | 1992-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU665176B2 (en) | Packaging cells | |
US5716832A (en) | Packaging cells | |
US5817491A (en) | VSV G pseusdotyped retroviral vectors | |
US7070994B2 (en) | Packaging cells | |
US5856185A (en) | Method for making reflection defective retroviral vectors for infecting human cells | |
JP3866760B2 (ja) | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 | |
EP1030861A1 (fr) | Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral | |
US6096534A (en) | Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells | |
US5766945A (en) | 10A1 Retroviral packaging cells and uses thereof | |
Somia | Gene transfer by retroviral vectors: an overview | |
US20030051259A1 (en) | Packaging cells | |
AU4312699A (en) | Lentiviral vectors | |
Schambach et al. | Retroviral vectors for cell and gene therapy | |
AU773576B2 (en) | Production of high titer helper-free retroviruses by transient transfection | |
US20030229903A1 (en) | Novel system for the evaluation of the activity and/or specificity of a viral component | |
WO1998050538A1 (fr) | LIGNEES CELLULAIRES D'ENCAPSIDATION RETROVIRALES ENDOGENES DE $i(MUS DUNNI) | |
Garoff et al. | Alphavirus-Retrovirus Vectors Henrik Garoff and Kejun Li Karolinska Institutet, Dept. of Biosciences at Novum 141 57 HUDDINGE, Sweden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930326 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19930715 |
|
18D | Application deemed to be withdrawn |
Effective date: 19941206 |
|
D18D | Application deemed to be withdrawn (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CHIRON VIAGENE, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CHIRON CORPORATION |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
R18D | Application deemed to be withdrawn (corrected) |
Effective date: 19980217 |